A thiadiazolylidene-morpholine compound inhibits Pseudomonas aeruginosa by destabilizing the thiamine monophosphate kinase thiL
Yingying Li, Jianqing Lin, Zara Chung, Benny Ken Yee Yeo, Julien Lescar, Kevin Pethe · 2026
Read A thiadiazolylidene-morpholine compound inhibits Pseudomonas aeruginosa by destabilizing the thiamine monophosphate kinase thiL by Yingying Li, Jianqing Lin, Zara Chung, Benny Ken Yee Yeo, Julien Lescar, Kevin Pethe (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13254938.txt.
Description
Yingying Li and co-authors validate a vitamin pathway enzyme as a drug target against a stubborn hospital pathogen, in a 2026 study. Pseudomonas aeruginosa resists many antibiotics and haunts lungs, wounds, and urinary tracts. Fresh targets are scarce.
Deleting the enzyme's gene stripped the bacteria of virulence in mouse lung and wound models, and the mutants survived only with flooded vitamin supply. A screen of more than twelve hundred kinase blockers found one compound that hits the enzyme squarely. It works by destabilizing the protein, which unfolds and loses function. The team pitches metabolic weak points as a route around drug resistance.
Catalog record
| CREATOR | Yingying Li, Jianqing Lin, Zara Chung, Benny Ken Yee Yeo, Julien Lescar, Kevin Pethe |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |